Inhibiting DOT1L can effectively reduce the transdifferentiation of mesothelial cells and phenotypic differentiation of macrophages into M2 macrophages, thereby alleviating peritoneal fibrosis. Here, DOT1L is linked to Peritoneal Fibrosis.